| http://purl.uniprot.org/citations/16476507 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/16476507 | http://www.w3.org/2000/01/rdf-schema#comment | "Recently, we demonstrated that the corticotropin releasing factor 2 receptor agonist, urocortin 2, demonstrated anti-atrophy effects in rodent skeletal muscle atrophy models. Compared to other CRF2R agonists however, the in vivo pharmacological potency of urocortin 2 is poor when it is administered by continuous subcutaneous infusion. Therefore, we attempted to modify the structure of urocortin 2 to improve in vivo efficacy when administered by subcutaneous infusion. By substituting amino acid residues in the linker region of urocortin 2 (residues 22-32), we have demonstrated improved in vivo potency without altering selectivity, probably through reduced CRFBP binding. In addition, attempts to shorten urocortin 2 generally resulted in inactive peptides, demonstrating that the 38 amino acid urocortin 2 peptide is the minimal pharmacophore."xsd:string |
| http://purl.uniprot.org/citations/16476507 | http://purl.org/dc/terms/identifier | "doi:10.1016/j.peptides.2006.01.003"xsd:string |
| http://purl.uniprot.org/citations/16476507 | http://purl.uniprot.org/core/author | "Wang F."xsd:string |
| http://purl.uniprot.org/citations/16476507 | http://purl.uniprot.org/core/author | "Reichart D."xsd:string |
| http://purl.uniprot.org/citations/16476507 | http://purl.uniprot.org/core/author | "Isfort R.J."xsd:string |
| http://purl.uniprot.org/citations/16476507 | http://purl.uniprot.org/core/author | "Dolan E."xsd:string |
| http://purl.uniprot.org/citations/16476507 | http://purl.uniprot.org/core/author | "Hinkle R.T."xsd:string |
| http://purl.uniprot.org/citations/16476507 | http://purl.uniprot.org/core/author | "Bauer M.B."xsd:string |
| http://purl.uniprot.org/citations/16476507 | http://purl.uniprot.org/core/author | "Keck B.D."xsd:string |
| http://purl.uniprot.org/citations/16476507 | http://purl.uniprot.org/core/author | "Lefever F."xsd:string |
| http://purl.uniprot.org/citations/16476507 | http://purl.uniprot.org/core/author | "Mazur A.W."xsd:string |
| http://purl.uniprot.org/citations/16476507 | http://purl.uniprot.org/core/author | "Reilman R.A."xsd:string |
| http://purl.uniprot.org/citations/16476507 | http://purl.uniprot.org/core/author | "Tscheiner M."xsd:string |
| http://purl.uniprot.org/citations/16476507 | http://purl.uniprot.org/core/author | "Wehmeyer K.R."xsd:string |
| http://purl.uniprot.org/citations/16476507 | http://purl.uniprot.org/core/date | "2006"xsd:gYear |
| http://purl.uniprot.org/citations/16476507 | http://purl.uniprot.org/core/name | "Peptides"xsd:string |
| http://purl.uniprot.org/citations/16476507 | http://purl.uniprot.org/core/pages | "1806-1813"xsd:string |
| http://purl.uniprot.org/citations/16476507 | http://purl.uniprot.org/core/title | "Modifications of the human urocortin 2 peptide that improve pharmacological properties."xsd:string |
| http://purl.uniprot.org/citations/16476507 | http://purl.uniprot.org/core/volume | "27"xsd:string |
| http://purl.uniprot.org/citations/16476507 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/16476507 |
| http://purl.uniprot.org/citations/16476507 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/16476507 |
| http://purl.uniprot.org/uniprot/#_Q96RP3-mappedCitation-16476507 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16476507 |
| http://purl.uniprot.org/uniprot/Q96RP3 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/16476507 |